Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...
MUMBAI/BENGALURU (Reuters) - Tariffs should not influence decisions at Indian drug companies, Cipla's top executive ... will make to us... and will not justify relocating our manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback